132 related articles for article (PubMed ID: 8901078)
1. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution.
Benziger DP; Kaiko RF; Miotto JB; Fitzmartin RD; Reder RF; Chasin M
J Pharm Sci; 1996 Apr; 85(4):407-10. PubMed ID: 8901078
[TBL] [Abstract][Full Text] [Related]
2. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
[TBL] [Abstract][Full Text] [Related]
4. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
5. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
[TBL] [Abstract][Full Text] [Related]
6. Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study.
Webster LR; Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Jul; 36(7):1730-1740. PubMed ID: 31065992
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.
Devarakonda K; Morton T; Margulis R; Giuliani M; Barrett T
Drug Des Devel Ther; 2014; 8():1125-34. PubMed ID: 25170252
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.
Scheidel B; Maritz MA; Gschwind YJ; Steigerwald K; Guth V; Kovacs P; Rey H
Int J Clin Pharmacol Ther; 2017 Nov; 55(11):881-890. PubMed ID: 28933336
[TBL] [Abstract][Full Text] [Related]
9. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.
Mandema JW; Kaiko RF; Oshlack B; Reder RF; Stanski DR
Br J Clin Pharmacol; 1996 Dec; 42(6):747-56. PubMed ID: 8971431
[TBL] [Abstract][Full Text] [Related]
10. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
Franke RM; Morton T; Devarakonda K
Drug Des Devel Ther; 2015; 9():4587-97. PubMed ID: 26316698
[TBL] [Abstract][Full Text] [Related]
11. Steady-state bioavailability of controlled-release oxycodone in normal subjects.
Reder RF; Oshlack B; Miotto JB; Benziger DD; Kaiko RF
Clin Ther; 1996; 18(1):95-105. PubMed ID: 8851456
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Bioequivalence Studies of an Extended-Release Oxycodone Hydrochloride Tablet in Healthy Japanese Subjects Under Fasting and Fed Conditions Without an Opioid Antagonist.
Toyama K; Furuie H; Kuroda K; Ishizuka H
Drugs R D; 2017 Sep; 17(3):363-370. PubMed ID: 28516342
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
14. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
Göhler K; Brett M; Smit JW; Rengelshausen J; Terlinden R
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):338-48. PubMed ID: 23357834
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food.
Kim TE; Kim JR; Jung JA; Kim MJ; Lee SY; Ko JW; Jung WT; Choi YW; Lee HJ; Kim SH; Huh W
J Clin Pharm Ther; 2014 Apr; 39(2):192-5. PubMed ID: 24325365
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone.
Webster LR; Bath B; Medve RA; Marmon T; Stoddard GJ
Pain Med; 2012 Jun; 13(6):790-801. PubMed ID: 22568663
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone.
Benziger DP; Miotto J; Grandy RP; Thomas GB; Swanton RE; Fitzmartin RD
J Pain Symptom Manage; 1997 Feb; 13(2):75-82. PubMed ID: 9095564
[TBL] [Abstract][Full Text] [Related]
19. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
20. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain.
Kaplan R; Parris WC; Citron ML; Zhukovsky D; Reder RF; Buckley BJ; Kaiko RF
J Clin Oncol; 1998 Oct; 16(10):3230-7. PubMed ID: 9779696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
